Kelly Huller Sells 10,000 Shares of Globus Medical (NYSE:GMED) Stock

Globus Medical, Inc. (NYSE:GMED) EVP Kelly Huller sold 10,000 shares of the stock in a transaction on Thursday, February 12th. The shares were sold at an average price of $87.67, for a total transaction of $876,700.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Kelly Huller also recently made the following trade(s):

• On Tuesday, November 25th, Kelly Huller sold 7,500 shares of Globus Medical stock. The shares were sold at an average price of $90.00, for a total value of $675,000.00.

Globus Medical Trading Up 1.0%

Shares of NYSE GMED traded up $0.92 during midday trading on Tuesday, hitting $89.01. The company’s stock had a trading volume of 782,778 shares, compared to its average volume of 1,418,392. Globus Medical, Inc. has a 12-month low of $51.79 and a 12-month high of $101.40. The firm has a market cap of $11.91 billion, a P/E ratio of 28.71, a price-to-earnings-growth ratio of 1.35 and a beta of 1.06. The business’s 50 day moving average is $89.66 and its two-hundred day moving average is $74.29.

Analyst Upgrades and Downgrades

Several research firms recently commented on GMED. Bank of America raised shares of Globus Medical from a “neutral” rating to a “buy” rating and raised their price target for the stock from $65.00 to $91.00 in a research note on Friday, November 7th. Royal Bank Of Canada raised their target price on shares of Globus Medical from $92.00 to $100.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. Piper Sandler reiterated an “overweight” rating and issued a $115.00 price target (up previously from $90.00) on shares of Globus Medical in a report on Thursday, January 8th. Wall Street Zen raised Globus Medical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 3rd. Finally, Canaccord Genuity Group lifted their target price on Globus Medical from $105.00 to $112.00 and gave the company a “buy” rating in a research report on Friday, January 9th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $100.18.

Institutional Trading of Globus Medical

A number of institutional investors have recently made changes to their positions in GMED. AQR Capital Management LLC grew its position in Globus Medical by 45.9% during the 1st quarter. AQR Capital Management LLC now owns 22,510 shares of the medical device company’s stock worth $1,622,000 after purchasing an additional 7,086 shares during the last quarter. Integrated Wealth Concepts LLC grew its position in Globus Medical by 33.0% during the 1st quarter. Integrated Wealth Concepts LLC now owns 4,375 shares of the medical device company’s stock worth $320,000 after purchasing an additional 1,085 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Globus Medical by 38.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,649 shares of the medical device company’s stock valued at $2,228,000 after buying an additional 8,540 shares during the last quarter. Jones Financial Companies Lllp lifted its holdings in shares of Globus Medical by 237.3% in the 1st quarter. Jones Financial Companies Lllp now owns 850 shares of the medical device company’s stock valued at $62,000 after buying an additional 598 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Globus Medical by 8.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 347,527 shares of the medical device company’s stock worth $25,439,000 after buying an additional 28,027 shares during the last quarter. Institutional investors and hedge funds own 95.16% of the company’s stock.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.